Webcast Features Research into ALS

September 1, 2004

New Webcast Series Reveals Potential for Neurodegenerative Disease Market Benefits to Patients, Biotech Firms, Pharmaceutical Firms

The possibility of following a shorter path to finding cures for ALS and other neuro-degenerative diseases by opening up a multi-billion dollar marketplace for innovative biotech and pharmaceutical companies is explored in a new webcast series produced by Killen & Associates. ALSA Science Director Lucie Bruijn is featured on the September 8 webcast.

"The Neurodegenerative Disease Market: Opportunities to Solve the Mysteries of Alzheimer's, Parkinson's, ALS, and Other Devastating Illnesses” webcasts feature four noted experts who describe the common underlying mechanisms of Alzheimer's, Parkinson's, ALS, MS, and others.

The experts’ insight creates a foundation for envisioning how biotech and pharmaceutical firms can shorten the time to find cures by leveraging the common elements of the major neurodegenerative diseases.

As the webcasts explain, there are common mechanisms underlying the major neurodegenerative disease. Firms that make breakthroughs in one disease area may have the technology necessary to open doors to other neurodegenerative disease markets as well.

To view a multimedia trailer of the series, visit http://www.killen.com/ndd/trailer. The series is available for general viewing at  http://www.killen.com/ndd. This webcast will be available for 18 months at this site.

For more information on the webcast series, contact Michael Killen of Killen & Associates at (650) 327-2312 or michael@killen.com. The company’s website is located at www.killen.com